Do analysts recommend NIOX or TSTL?

NIOX Group currently has a consensus target price of GBX 86, indicating a potential upside of 27.22%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, NIOX or TSTL?

NIOX Group has higher earnings, but lower revenue than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NIOX Group £47.50M 5.99 £995.88M £1.63 41.47 Tristel £49.54M 4.20 £6.54M £16.24 26.63

Is NIOX or TSTL more profitable?

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.74%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity. Company Net Margins Return on Equity Return on Assets NIOX Group 14.74% 10.01% 3.95% Tristel 15.88% 23.64% 9.89%

Do analysts rate TSTL or EKF?

EKF Diagnostics has a consensus price target of GBX 35, suggesting a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is TSTL or EKF more profitable?

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.86%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.88% 23.64% 9.89% EKF Diagnostics 4.86% 3.58% 5.27%

Does the media prefer TSTL or EKF?

In the previous week, EKF Diagnostics had 1 more articles in the media than Tristel. MarketBeat recorded 2 mentions for EKF Diagnostics and 1 mentions for Tristel. EKF Diagnostics' average media sentiment score of 0.37 beat Tristel's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tristel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral EKF Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TSTL or SPEC more profitable?

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.88% 23.64% 9.89% INSPECS Group -0.52% -1.19% 0.45%

Tristel (TSTL) Competitors

GBX 430 -2.50 (-0.58%)

As of 04:23 AM Eastern

Compare

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

Should you buy Tristel stock or one of its competitors? Tristel's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Tristel has a net margin of 15.88% compared to Advanced Medical Solutions Group's net margin of 1.58%. Tristel's return on equity of 23.64% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Medical Solutions Group	1.58%	1.44%	2.35%
Tristel	15.88%	23.64%	9.89%

Advanced Medical Solutions Group has a beta of 0.704, meaning that its share price is 30% less volatile than the broader market. Comparatively, Tristel has a beta of 0.352, meaning that its share price is 65% less volatile than the broader market.

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Solutions Group	£233.63M	2.63	£11.22M	£1.65	170.91
Tristel	£49.54M	4.20	£6.54M	£16.24	26.63

Advanced Medical Solutions Group currently has a consensus price target of GBX 278.33, indicating a potential downside of 1.30%. Given Advanced Medical Solutions Group's stronger consensus rating and higher probable upside, analysts plainly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Solutions Group	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.5% of Advanced Medical Solutions Group shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 4.0% of Advanced Medical Solutions Group shares are owned by insiders. Comparatively, 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tristel had 1 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for Advanced Medical Solutions Group. Advanced Medical Solutions Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
Advanced Medical Solutions Group	Neutral
Tristel	Neutral

Advanced Medical Solutions Group pays an annual dividend of GBX 2.86 per share and has a dividend yield of 1.0%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.3%. Advanced Medical Solutions Group pays out 173.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Tristel beats Advanced Medical Solutions Group on 10 of the 17 factors compared between the two stocks.

How does Tristel compare to NIOX Group?

NIOX Group (LON:NIOX) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

NIOX Group currently has a consensus target price of GBX 86, indicating a potential upside of 27.22%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NIOX Group has higher earnings, but lower revenue than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£47.50M	5.99	£995.88M	£1.63	41.47
Tristel	£49.54M	4.20	£6.54M	£16.24	26.63

NIOX Group has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Tristel has a beta of 0.352, meaning that its stock price is 65% less volatile than the broader market.

In the previous week, Tristel had 1 more articles in the media than NIOX Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for NIOX Group. NIOX Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
NIOX Group	Neutral
Tristel	Neutral

7.6% of NIOX Group shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 5.1% of NIOX Group shares are owned by insiders. Comparatively, 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.74%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.74%	10.01%	3.95%
Tristel	15.88%	23.64%	9.89%

NIOX Group pays an annual dividend of GBX 1.55 per share and has a dividend yield of 2.3%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.3%. NIOX Group pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Tristel beats NIOX Group on 10 of the 17 factors compared between the two stocks.

How does Tristel compare to EKF Diagnostics?

Tristel (LON:TSTL) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

22.4% of Tristel shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, EKF Diagnostics had 1 more articles in the media than Tristel. MarketBeat recorded 2 mentions for EKF Diagnostics and 1 mentions for Tristel. EKF Diagnostics' average media sentiment score of 0.37 beat Tristel's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tristel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
EKF Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

EKF Diagnostics has a consensus price target of GBX 35, suggesting a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.86%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
EKF Diagnostics	4.86%	3.58%	5.27%

Tristel has a beta of 0.352, meaning that its share price is 65% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, meaning that its share price is 50% less volatile than the broader market.

Tristel has higher earnings, but lower revenue than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	4.20	£6.54M	£16.24	26.63
EKF Diagnostics	£51.35M	2.17	£4.68M	£0.58	44.83

Summary

EKF Diagnostics beats Tristel on 9 of the 16 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Tristel has a beta of 0.352, suggesting that its share price is 65% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, suggesting that its share price is 60% more volatile than the broader market.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
INSPECS Group	-0.52%	-1.19%	0.45%

22.4% of Tristel shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 19.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	4.20	£6.54M	£16.24	26.63
INSPECS Group	£193.23M	0.51	-£4.11M	-£5.34	N/A

In the previous week, Tristel had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
INSPECS Group	Neutral

Summary

Tristel beats INSPECS Group on 10 of the 12 factors compared between the two stocks.

How does Tristel compare to Creo Medical Group?

Tristel (LON:TSTL) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	4.20	£6.54M	£16.24	26.63
Creo Medical Group	£7M	6.90	-£25.04M	-£5.00	N/A

Tristel has a beta of 0.352, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market.

22.4% of Tristel shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 7.0% of Creo Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Tristel had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for Creo Medical Group. Tristel's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
Creo Medical Group	Neutral

Tristel has a net margin of 15.88% compared to Creo Medical Group's net margin of -268.57%. Tristel's return on equity of 23.64% beat Creo Medical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
Creo Medical Group	-268.57%	-38.29%	-20.09%

Summary

Tristel beats Creo Medical Group on 9 of the 12 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSTL vs. The Competition

Export

Metric	Tristel	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£206.71M	£5.49B	£7.25B	£2.80B
Dividend Yield	3.30%	1.77%	2.52%	6.27%
P/E Ratio	26.48	25.57	275.59	367.14
Price / Sales	4.17	71.17	595.08	88,583.36
Price / Cash	20.96	32.56	27.30	27.87
Price / Book	6.29	5.95	10.97	7.26
Net Income	£6.54M	£146.14M	£3.50B	£5.89B
7 Day Performance	2.60%	-0.62%	-1.20%	0.00%
1 Month Performance	8.16%	-2.16%	-4.00%	-0.57%
1 Year Performance	20.11%	5.37%	7.14%	22.53%

Tristel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSTL Tristel	N/A	GBX 430 -0.6%	N/A	+20.8%	£206.71M	£49.54M	26.48	208
AMS Advanced Medical Solutions Group	0.2102 of 5 stars	GBX 282.01 -0.2%	GBX 278.33 -1.3%	+24.5%	£613.95M	£233.63M	170.92	10	Positive News
NIOX NIOX Group	1.6988 of 5 stars	GBX 68.40 +0.3%	GBX 86 +25.7%	-9.4%	£287.87M	£47.50M	41.96	92	Positive News Gap Up
EKF EKF Diagnostics	2.5621 of 5 stars	GBX 24.80 +2.5%	GBX 35 +41.1%	-9.7%	£106.14M	£51.35M	42.76	356	Gap Up
SPEC INSPECS Group	N/A	GBX 89.65 -0.4%	N/A	+97.0%	£97.88M	£193.23M	N/A	1,673

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tristel (TSTL) Competitors

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

How does Tristel compare to Advanced Medical Solutions Group?

Summary

How does Tristel compare to NIOX Group?

Summary

How does Tristel compare to EKF Diagnostics?

Summary

How does Tristel compare to INSPECS Group?

Summary

How does Tristel compare to Creo Medical Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tristel (TSTL) Competitors

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

How does Tristel compare to Advanced Medical Solutions Group?

Is AMS or TSTL more profitable?

Which has more volatility & risk, AMS or TSTL?

Which has stronger earnings and valuation, AMS or TSTL?

Do analysts prefer AMS or TSTL?

Do institutionals & insiders have more ownership in AMS or TSTL?

Does the media prefer AMS or TSTL?

Is AMS or TSTL a better dividend stock?

Summary

How does Tristel compare to NIOX Group?

Do analysts recommend NIOX or TSTL?

Which has stronger earnings & valuation, NIOX or TSTL?

Which has more volatility and risk, NIOX or TSTL?

Does the media refer more to NIOX or TSTL?

Do insiders and institutionals hold more shares of NIOX or TSTL?

Is NIOX or TSTL more profitable?

Is NIOX or TSTL a better dividend stock?

Summary

How does Tristel compare to EKF Diagnostics?

Do insiders & institutionals hold more shares of TSTL or EKF?

Does the media prefer TSTL or EKF?

Do analysts rate TSTL or EKF?

Is TSTL or EKF more profitable?

Which has more volatility & risk, TSTL or EKF?

Which has preferable valuation & earnings, TSTL or EKF?

Summary

How does Tristel compare to INSPECS Group?

Which has more risk & volatility, TSTL or SPEC?

Is TSTL or SPEC more profitable?

Do insiders and institutionals hold more shares of TSTL or SPEC?

Which has stronger earnings and valuation, TSTL or SPEC?

Does the media refer more to TSTL or SPEC?

Summary

How does Tristel compare to Creo Medical Group?

Which has higher earnings and valuation, TSTL or CREO?

Which has more volatility and risk, TSTL or CREO?

Do institutionals & insiders believe in TSTL or CREO?

Does the media refer more to TSTL or CREO?

Is TSTL or CREO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools